Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Ajovy, Ajovy autoinjector
Synonyms :
fremanezumab
Class :
Calcitonin gene-related peptide inhibitors
Brand Name :
Ajovy, Ajovy autoinjector
Synonyms :
fremanezumab
Class :
Calcitonin gene-related peptide inhibitors
Dosage Forms & StrengthsÂ
Injectable solutionÂ
225mg/1.5ml (single dose prefilled autoinjector)Â
Indicated for the migraine preventive treatment:
225
mg
Solution
Subcutaneous (SC)
once every month
Alternative: 3 consecutive 225mg subcutaneous dosages of 675 mg every three months (quarterly)
Dose Adjustments
Hepatic impairment
Dedicated studies on the effects of hepatic impairment on fremanezumab have yet to be performed. The data analysis from clinical studies indicated no differences in the pharmacokinetics in patients with mild liver dysfunction
Renal impairment
The pharmacokinetics are not anticipated to be affected, and no specific studies have been done to examine renal impairment
Safety and efficacy not establishedÂ
Refer adult dosingÂ
may increase the risk or severity of adverse effects when combined
may increase the risk or severity of adverse effects when combined
may increase the risk or severity of adverse effects when combined
may increase the risk or severity of adverse effects when combined
may increase the risk or severity of adverse effects when combined
measles, mumps, rubella, and varicella vaccine, live (Rx)
immune globulins: it may decrease the therapeutic effect of vaccines (Live)
measles mumps and rubella vaccine, live
immune globulins: it may decrease the therapeutic effect of vaccines (Live)
immune globulins: it may decrease the therapeutic effect of vaccines (Live)
smallpox (vaccinia) vaccine, live
immune globulins: it may decrease the therapeutic effect of vaccines (Live)
immune globulins: it may decrease the therapeutic effect of vaccines (Live)
respiratory syncytial virus vaccine, adjuvanted
may decrease the therapeutic effect when combined with Vaccines
respiratory syncytial virus (RSV) vaccine
may decrease the therapeutic effect when combined with Vaccines
poliovirus vaccine, live, trivalent
may decrease the therapeutic effect when combined with Vaccines
poliovirus vaccine inactivated
may decrease the therapeutic effect when combined with Vaccines
respiratory syncytial virus vaccine, adjuvanted
may decrease the therapeutic effect when combined with Vaccines
respiratory syncytial virus (RSV) vaccine
may decrease the therapeutic effect when combined with Vaccines
may decrease the therapeutic effect when combined with Vaccines
may increase the risk or severity of adverse effects when combined
may increase the risk or severity of adverse effects when combined
may increase the risk or severity of adverse effects when combined
may increase the risk or severity of adverse effects when combined
may increase the risk of adverse effects when combined
may decrease the therapeutic activity of Fc receptor-binding agents
may increase the risk or severity of adverse effects when combined
may increase the risk or severity of adverse effects when combined
may increase the risk or severity of adverse effects when combined
It may enhance the adverse effects when combined with sotrovimab
measles, mumps, rubella, and varicella vaccine, live (Rx)
immune globulins decrease the efficacy of live vaccines
measles mumps and rubella vaccine, live
immune globulins decrease the efficacy of live vaccines
immune globulins decrease the efficacy of live vaccines
smallpox (vaccinia) vaccine, live
immune globulins decrease the efficacy of live vaccines
immune globulins decrease the efficacy of live vaccines
May have an increased the thrombogenic effect when combined with anthrax immune globulin
May have an increased the thrombogenic effect when combined with anthrax immune globulin
bazedoxifene/conjugated estrogens
May have an increased the thrombogenic effect when combined with anthrax immune globulin
May have an increased the thrombogenic effect when combined with anthrax immune globulin
May have an increased the thrombogenic effect when combined with anthrax immune globulin
may have an increased thrombogenic effect when combined with anthrax immune globulin
may have an increased thrombogenic effect when combined with anthrax immune globulin
Mechanism of actionÂ
It is a monoclonal antibody that targets the calcitonin gene-related peptide (CGRP) receptor. The CGRP receptor is involved in the pathogenesis of migraines and cluster headaches. By binding to the receptor, fremanezumab blocks the action of CGRP and reduces the inflammation and pain associated with migraines.Â
SpectrumÂ
The spectrum of activity of fremanezumab is limited to treating migraines and cluster headaches.Â
Frequency defined:Â Â
1-10%Â
Pain at the injection siteÂ
Post-marketing reportsÂ
AngioedemaÂ
Anaphylactic reactionsÂ
ContraindicationsÂ
It should be avoided in patients with severe allergic reactions to it or its components. It should also be used with caution in patients with a history of serious infections, as using monoclonal antibodies may increase the risk of infections.Â
CautionÂ
Pregnancy consideration: Insufficient data availableÂ
AU TGA Pregnancy category: B1Â
Lactation: Excretion of the drug in human breast milk is unknownÂ
Pregnancy category:Â
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.  Â
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.Â
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.   Â
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.   Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.   Â
Category N: There is no data available for the drug under this categoryÂ
PharmacologyÂ
It is a humanized monoclonal antibody that targets the calcitonin gene-related peptide (CGRP) receptor. The CGRP receptor is involved in the pathogenesis of migraines and cluster headaches. By binding to the receptor, fremanezumab blocks the action of CGRP and reduces the inflammation and pain associated with migraines.Â
PharmacodynamicsÂ
The pharmacodynamic effect of fremanezumab can be observed by a decrease in the frequency, intensity, and duration of migraines. It also reduces the number of days with migraine-associated symptoms, such as nausea, vomiting, and photophobia.Â
PharmacokineticsÂ
Absorption:Â
It is rapidly and extensively absorbed after subcutaneous administration, with peak plasma concentrations occurring within 1-2 days.Â
Distribution:Â
The drug has a large volume of distribution, which is 6 liters. Â
Metabolism:Â
Enzymatic proteolysis of fremanezumab occurs primarily in the liver and is mediated by a group of enzymes called proteases. Â
Elimination/Excretion:Â
The elimination half-life of the drug is approximately 20 days. Clearance of the drug is approximately 0.141L/day.Â
AdministrationÂ
Subcutaneous administrationÂ
The therapy may be administered by healthcare professionals, patients, and caregivers. Proper training should be provided to patients and caregivers on the preparation and administration of the prefilled syringe, including the aseptic technique.Â
The subcutaneous (SC) injections should be given in areas of the abdomen, thigh, or upper arm that are not tender, bruised, red, or indurated. For multiple injections, the same body site should be used, but not the exact location of the previous injection, to reduce the risk of soreness or irritation.Â
It is also important to note that fremanezumab should not be co-administered with other injectable drugs at the same injection site. This is to avoid confusion or errors in administering the medications and to minimize the risk of adverse reactions.Â
StorageÂ
Patient information leafletÂ
Generic Name: fremanezumabÂ
Pronounced: [ FREE-ma-NEZ-ue-mab ]Â
Why do we use fremanezumab?Â
fremanezumab is used in the preventive treatment of migraines and cluster headaches.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
